Abstract: CP-673451 is a potent and highly selective inhibitor of platelet-derived growth factor receptors (PDGFRs), particularly PDGFRβ, which has demonstrated significant potential in oncology research. This comprehensive review synthesizes current findings on the pharmacological activities and molecular mechanisms of CP-673451 across various cancer models. In non-small-cell lung cancer (NSCLC) and rhabdomyosarcoma (RMS), CP-673451 exhibits robust anti-tumor effects by suppressing cell viability, inducing apoptosis, and inhibiting migration, invasion, and angiogenesis through the blockade of PDGFR-mediated downstream signaling pathways, including PI3K/Akt and GSK-3β. Furthermore, recent studies have unveiled a novel, PDGFR-independent mechanism of action: CP-673451 acts as a robust inhibitor of centrosome clustering in cancer cells with centrosome amplification. By activating the actin-severing protein cofilin via slingshot phosphatases, the compound destabilizes the cortical actin network, selectively inducing multipolar cell divisions and death in malignant cells. Despite its therapeutic promise, challenges such as heterogeneous cellular responses and paradoxical signaling activation in non-stimulated cells remain. Future perspectives highlight its potential as a targeted therapy for tumors exhibiting PDGFR overexpression or centrosome amplification.
1. Introduction
The platelet-derived growth factor receptors (PDGFRs) and their ligands play critical roles in regulating essential cellular processes, including proliferation, survival, migration, and angiogenesis [1]. Aberrant PDGFR signaling, often driven by overexpression or autocrine/paracrine loops, is implicated in the pathogenesis and metastasis of numerous human malignancies, making it an attractive therapeutic target [1][3]. CP-673451 is a potent, ATP-competitive small-molecule inhibitor of PDGFR kinase, exhibiting more than 450-fold selectivity for PDGFRβ over other receptor tyrosine kinases [1]. Recent oncology research has expanded the understanding of CP-673451, demonstrating its efficacy not only as a targeted PDGFR inhibitor in solid tumors like non-small-cell lung cancer (NSCLC) and rhabdomyosarcoma (RMS) [1][3], but also as a novel disruptor of centrosome clustering in cancer cells harboring supernumerary centrosomes [2]. This review outlines the pharmacological activity, molecular mechanisms, structure-activity relationships, limitations, and future therapeutic potential of CP-673451.
2. Pharmacological Activity
CP-673451 has demonstrated diverse pharmacological activities across multiple in vitro and in vivo cancer models:
Non-Small-Cell Lung Cancer (NSCLC): CP-673451 significantly reduces the viability of NSCLC cell lines (e.g., A549 and H1299) in a time- and dose-dependent manner, with IC50 values of approximately 0.49 and 0.61 µM, respectively [1]. It induces apoptosis, evidenced by increased sub-G1 DNA content and fragmented nuclei. Furthermore, CP-673451 strongly inhibits cancer cell migration and invasion by suppressing actin reorganization and lamellipodia formation. In vivo, oral administration of CP-673451 (20-40 mg/kg) effectively suppresses A549 tumor xenograft growth without significant systemic toxicity or body weight loss [1].
Rhabdomyosarcoma (RMS): In pediatric RMS models, CP-673451 targets both the tumor and stromal compartments. It decreases cell proliferation and survival in PDGFR-positive RMS cell lines (such as RD and RUCH2) [3]. The compound induces G2/M cell cycle arrest and apoptosis in RUCH2 cells, while triggering senescence and impaired myogenic differentiation in RD cells. It also impairs anchorage-independent rhabdosphere formation, indicating a suppression of cancer cell stemness. In vivo, CP-673451 reduces tumor burden, decreases vessel density, and limits macrophage infiltration in RUCH2 xenografts [3].
Inhibition of Centrosome Clustering: A high-throughput screen identified CP-673451 as a robust inhibitor of centrosome clustering (CC) [2]. Cancer cells frequently exhibit centrosome amplification (CA) and rely on CC to avoid lethal multipolar cell divisions. CP-673451 selectively eradicates cells with extra centrosomes by inducing multipolar mitotic spindles, leading to mitotic catastrophe and cell death, while sparing normal cells with standard centrosome counts [2].
3. Molecular Mechanism of Action
The mechanisms underlying the anti-tumor effects of CP-673451 can be categorized into PDGFR-dependent and PDGFR-independent pathways.
PDGFR-Dependent Signaling Inhibition: As a selective PDGFR inhibitor, CP-673451 blocks ligand-induced receptor autophosphorylation. In NSCLC cells, this blockade efficiently suppresses downstream PI3K/Akt signaling, leading to reduced phosphorylation of Akt, GSK-3β, p70S6K, and S6 proteins [1]. Similarly, in RMS cells, CP-673451 abolishes PDGF-CC-induced phosphorylation of Akt, GSK-3α, and GSK-3β, which correlates with its anti-proliferative and pro-apoptotic effects [3]. By inhibiting these pathways, CP-673451 disrupts the critical signals required for tumor cell survival, stemness maintenance, and lamellipodia-driven motility [1][3].
PDGFR-Independent Actin Cortex Destabilization: The ability of CP-673451 to inhibit centrosome clustering is independent of its PDGFR-β inhibitory activity [2]. Instead, CP-673451 induces the activation (dephosphorylation at Ser3) of cofilin, an actin-severing protein. This activation is mediated by the stimulation of slingshot phosphatases (SSH1 and SSH2). The accumulation of active cofilin during mitosis destabilizes the cortical actin meshwork, which is essential for generating the forces required to cluster supernumerary centrosomes. Consequently, the loss of cortical actin integrity forces cancer cells with amplified centrosomes into lethal multipolar divisions [2].
4. Structure-Activity Relationship (SAR)
CP-673451 is chemically classified as a quinolinobenzimidazole derivative, specifically 1-(2-(5-(2-methoxyethoxy)-1H-benzo[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine [2]. It shares significant structural homology with crenolanib (CP-868596), another potent PDGFR inhibitor. Both compounds feature aminopiperidine, quinoline, and benzimidazole ring systems [2]. CP-673451 functions as a type I tyrosine kinase inhibitor (TKI), meaning it acts as an ATP-competitive inhibitor that preferentially binds to the active conformation of receptor tyrosine kinases [2]. This structural configuration grants CP-673451 its extreme selectivity for PDGFRβ over other related receptors [1].
5. Current Limitations
Despite its efficacy, several limitations and complexities are associated with CP-673451 therapy:
- Heterogeneous Cellular Responses: The biological response to CP-673451 can vary significantly depending on the cellular context. For instance, in RMS, while RUCH2 cells undergo apoptosis and cell cycle arrest, RD cells primarily exhibit senescence and impaired differentiation without massive apoptosis [3]. Furthermore, in tumors where PDGFR expression is restricted strictly to the stroma (and absent in tumor cells), CP-673451 fails to reduce tumor growth or vessel density, indicating that stromal targeting alone may be insufficient in certain contexts [3].
- Paradoxical Signaling Activation: Because CP-673451 is a type I TKI that binds active receptor conformations, it effectively attenuates signaling in PDGF-stimulated cells. However, in non-stimulated, serum-starved cancer cells, exposure to CP-673451 paradoxically enhances the phosphorylation of downstream effectors like Akt and MEK [2]. This unintended kinase activation could potentially promote survival signals in certain microenvironments, complicating its therapeutic use.
6. Future Perspectives
The dual mechanism of CP-673451—acting both as a targeted PDGFR inhibitor and a disruptor of centrosome clustering—opens novel avenues for cancer therapy. Future research should focus on exploiting its selective cytotoxicity against cells with centrosome amplification (CA), a hallmark of many aggressive solid tumors and hematological malignancies [2]. Because normal cells lack extra centrosomes, CP-673451 could offer a wide therapeutic window for CA-positive cancers. Additionally, patient stratification based on tumor versus stromal PDGFR expression profiles will be crucial for maximizing clinical efficacy, particularly in sarcomas [3]. Combination therapies that pair CP-673451 with agents targeting paradoxical Akt/MEK activation or other complementary pathways (such as VEGFR inhibitors) may overcome current limitations and prevent resistance, shedding new light on the management of refractory cancers like NSCLC and RMS [1][3].
